Literature DB >> 16821091

Proposal of a scoring scale as a survival predictor in intracranial oligodendrogliomas.

Abderrahmane Hamlat1, Stephan Saikali, Jacques Chaperon, Beatrice Carsin-Nicol, Michéle Le Calve, Thierry Lesimple, Mohamed Ben-hassel, Yvon Guegan.   

Abstract

INTRODUCTION: Histological, clinical and radiological features, and molecular genetic analysis are among the factors that have been considered in defining the prognosis of oligodendrogliomas (OD), but they have yielded conflicting results. The purpose of this study was to test out a scoring scale based on clinical, radiological, pathological and molecular features. MATERIAL AND
METHOD: To identify factors with prognostic significance, we analyzed 87 treated patients with a histological diagnosis of OD. Of the parameters analyzed, age, onset, clinical status, radiological enhancement, histological necrosis, mitosis and chromosomal anomalies emerged as significant prognosis factors using univariate analysis. Multivariate analysis revealed age and chromosomal anomalies as independent factors of survival.
RESULTS: The factors with a significant prognostic value were combined to determine which grouping factors best predict outcome. The proposed score is a pure number resulting from a combination of: 2 major factors: age and chromosomal anomalies (scored 3-0); 5 minor factors: onset, clinical examination, necrosis, mitoses (scored 1-0), and radiological enhancement (scored 2-0). According to our scale, 10 survival curves were produced for overall survival. Recursive partitioning of patients with the nearest score and outcome produced four groups with a significant difference in survival (p=10(-5)). The power of both the scale and the partitioned groups for predicting outcome was more accurate than the WHO and St Anne grading systems, and the molecular sub-classification.
CONCLUSIONS: Our scale is a plausible way of classifying patients harboring intracranial OD according to expected survival.

Entities:  

Mesh:

Year:  2006        PMID: 16821091     DOI: 10.1007/s11060-005-9026-8

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  43 in total

1.  Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas.

Authors:  J S Smith; A Perry; T J Borell; H K Lee; J O'Fallon; S M Hosek; D Kimmel; A Yates; P C Burger; B W Scheithauer; R B Jenkins
Journal:  J Clin Oncol       Date:  2000-02       Impact factor: 44.544

Review 2.  PCV chemotherapy for oligodendroglioma: response analyzed on T2 weighted-MRI.

Authors:  S Diabira; M C Rousselet; E Gamelin; P Soulier; E Jadaud; P Menei
Journal:  J Neurooncol       Date:  2001-10       Impact factor: 4.130

3.  Oligodendrogliomas in the CT/MR-era.

Authors:  M A Leonardi; C B Lumenta
Journal:  Acta Neurochir (Wien)       Date:  2001-12       Impact factor: 2.216

Review 4.  Recent developments in the molecular characterization and treatment of oligodendroglial tumors.

Authors:  Martin van den Bent; Olivier-Louis Chinot; J Gregory Cairncross
Journal:  Neuro Oncol       Date:  2003-04       Impact factor: 12.300

5.  Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization.

Authors:  S H Bigner; M R Matthews; B K Rasheed; R N Wiltshire; H S Friedman; A H Friedman; T T Stenzel; D M Dawes; R E McLendon; D D Bigner
Journal:  Am J Pathol       Date:  1999-08       Impact factor: 4.307

6.  Treatment outcomes and prognostic factors of patients with supratentorial low-grade oligodendroglioma.

Authors:  Shyh-An Yeh; Tao-Chen Lee; Han-Jung Chen; Chun-Chung Lui; Li-Min Sun; Chong-Jong Wang; Eng-Yen Huang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-12-01       Impact factor: 7.038

Review 7.  Oligodendroglioma: pathology and molecular biology.

Authors:  Herbert H Engelhard; Ana Stelea; Elizabeth J Cochran
Journal:  Surg Neurol       Date:  2002-08

Review 8.  The WHO classification of tumors of the nervous system.

Authors:  Paul Kleihues; David N Louis; Bernd W Scheithauer; Lucy B Rorke; Guido Reifenberger; Peter C Burger; Webster K Cavenee
Journal:  J Neuropathol Exp Neurol       Date:  2002-03       Impact factor: 3.685

9.  Oligodendrogliomas: the Mayo Clinic experience.

Authors:  E G Shaw; B W Scheithauer; J R O'Fallon; H D Tazelaar; D H Davis
Journal:  J Neurosurg       Date:  1992-03       Impact factor: 5.115

10.  Prognostic significance of tumor-enhancement and angiogenesis in oligodendroglioma.

Authors:  J Vaquero; M Zurita; C Morales; S Coca
Journal:  Acta Neurol Scand       Date:  2002-07       Impact factor: 3.209

View more
  2 in total

Review 1.  Factors affecting prognosis of patients with intracranial anaplastic oligodendrogliomas: a single institutional review of 70 patients.

Authors:  Liu-song Yang; Feng-ping Huang; Kang Zheng; Hai-shi Zhang; Xiang Zhou; Xu-hui Bao; Jia-jun Zheng; Chuan Chang; Liang-fu Zhou
Journal:  J Neurooncol       Date:  2010-02-27       Impact factor: 4.130

2.  Health-related quality of life and cognitive functioning in long-term anaplastic oligodendroglioma and oligoastrocytoma survivors.

Authors:  Esther J J Habets; Martin J B Taphoorn; Sylvie Nederend; Martin Klein; Daniel Delgadillo; Khê Hoang-Xuan; Andrew Bottomley; Anouk Allgeier; Tatjana Seute; Anja M M Gijtenbeek; Jan de Gans; Roelien H Enting; Cees C Tijssen; Martin J van den Bent; Jaap C Reijneveld
Journal:  J Neurooncol       Date:  2013-10-26       Impact factor: 4.130

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.